clinical trial · NCT05415462
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
ModernaTX, Inc.·phase3·completed·n = 6,102
Seasonal InfluenzamRNA-1010Fluarix Tetra
brief summary
The primary objectives of this study are to evaluate the humoral immunogenicity of mRNA-1010 relative to that of an active comparator against vaccine-matched influenza A and B strains at Day 29, and to evaluate the safety and reactogenicity of mRNA-1010.
started
Jun 6, 2022
primary completion
Sep 4, 2023
completion
Sep 4, 2023
last updated
Sep 24, 2024
official title
A Phase 3, Randomized, Stratified, Observer-blind, Active-Controlled Study to Evaluate the Immunogenicity and Safety of mRNA-1010 Seasonal Influenza Vaccine in Adults 18 Years and Older
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol